## Marcel Ruzicka

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2546362/publications.pdf

Version: 2024-02-01

59	2,742	18 h-index	51
papers	citations		g-index
60	60	60	3988
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
2	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
3	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
4	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	0.8	324
5	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
6	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
7	BpTRUth: Do automated blood pressure monitors outperform mercury?. Journal of the American Society of Hypertension, 2013, 7, 448-453.	2.3	36
8	Renal infarct in a COVID-19–positive kidney–pancreas transplant recipient. American Journal of Transplantation, 2020, 20, 3221-3224.	2.6	35
9	Are Automated Blood Pressure Monitors Comparable to Ambulatory Blood Pressure Monitors? A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2017, 33, 644-652.	0.8	33
10	Performance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2423-2435.	1.8	32
11	Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. American Journal of Kidney Diseases, 2014, 63, 869-887.	2.1	31
12	Vascular Aging: Lessons From Pediatric Hypertension. Canadian Journal of Cardiology, 2016, 32, 642-649.	0.8	29
13	How Accurate Are Home Blood Pressure Devices in Use? A Cross-Sectional Study. PLoS ONE, 2016, 11, e0155677.	1.1	29
14	Do high doses of AT1-receptor blockers attenuate central sympathetic outflow in humans with chronic heart failure?. Clinical Science, 2013, 124, 589-595.	1.8	27
15	Hypertension Canada's 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension. Canadian Journal of Cardiology, 2020, 36, 625-634.	0.8	27
16	What is the feasibility of implementing effective sodium reduction strategies to treat hypertension in primary care settings? A systematic review. Journal of Hypertension, 2014, 32, 1388-1394.	0.3	24
17	Heat Tolerance and Occupational Heat Exposure Limits in Older Men with and without Type 2 Diabetes or Hypertension. Medicine and Science in Sports and Exercise, 2021, 53, 2196-2206.	0.2	24
18	Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study. American Journal of Kidney Diseases, 2021, 77, 178-189.e1.	2.1	21

#	Article	IF	CITATIONS
19	Effect of hemodialysis on extracellular vesicles and circulating submicron particles. BMC Nephrology, 2019, 20, 294.	0.8	19
20	Use of Directly Observed Therapy to Assess Treatment Adherence in Patients With Apparent Treatment-Resistant Hypertension. JAMA Internal Medicine, 2019, 179, 1433.	2.6	19
21	Alpha-Blocker Use and the Risk of Hypotension and Hypotension-Related Clinical Events in Women of Advanced Age. Hypertension, 2019, 74, 645-651.	1.3	18
22	Can Drugs Work in Patients Who Do Not Take Them? The Problem of Non-adherence in Resistant Hypertension. Current Hypertension Reports, 2015, 17, 579.	1.5	17
23	The Effects of Lysine Analogs During Pelvic Surgery: A Systematic Review and Meta-Analysis. Transfusion Medicine Reviews, 2014, 28, 145-155.	0.9	16
24	Short Daily versus Conventional Hemodialysis for Hypertensive Patients: A Randomized Cross-Over Study. PLoS ONE, 2014, 9, e97135.	1.1	16
25	Adherence to Blood Pressure–Lowering Drugs and Resistant Hypertension: Should Trial of Direct Observation Therapy Be Part of Preassessment for Renal Denervation?. Canadian Journal of Cardiology, 2013, 29, 1741.e1-1741.e3.	0.8	12
26	Percutaneous Renal Sympathetic Denervation: 2013 andÂBeyond. Canadian Journal of Cardiology, 2014, 30, 64-74.	0.8	11
27	The association of urinary sodium excretion and the need for renal replacement therapy in advanced chronic kidney disease: a cohort study. BMC Nephrology, 2016, 17, 123.	0.8	11
28	Effects of CPAP on Blood Pressure and Sympathetic Activity in Patients With Diabetes Mellitus, Chronic Kidney Disease, and Resistant Hypertension. CJC Open, 2020, 2, 258-264.	0.7	11
29	Treatment of hypertension in patients with nondiabetic chronic kidney disease. Canadian Journal of Cardiology, 2007, 23, 595-601.	0.8	9
30	Microparticle Formation in Peritoneal Dialysis. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769982.	0.6	9
31	Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients. PLoS ONE, 2017, 12, e0187269.	1.1	9
32	Longitudinal Blood Pressure in Late-Stage Chronic Kidney Disease and the Risk of End-Stage Kidney Disease or Mortality (Best Blood Pressure in Chronic Kidney Disease Study). Hypertension, 2017, 70, 1210-1218.	1.3	8
33	Impact of uncomplicated controlled hypertension on thermoregulation during exercise-heat stress. Journal of Human Hypertension, 2020, 35, 880-883.	1.0	8
34	Accuracyâ€"Limiting Factor of Home Blood Pressure Monitors?. American Journal of Hypertension, 2017, 30, 661-664.	1.0	7
35	Precision Medicine for Hypertension Management in Chronic Kidney Disease: Relevance of SPRINT for Therapeutic Targets in Nondiabetic Renal Disease. Canadian Journal of Cardiology, 2017, 33, 611-618.	0.8	7
36	The Hypertension Canada blood pressure device recommendation listing: Empowering use of clinically validated devices in Canada. Journal of Clinical Hypertension, 2020, 22, 933-936.	1.0	7

#	Article	IF	CITATIONS
37	Balancing Overscreening and Underdiagnosis in Secondary Hypertension. Cardiology Clinics, 2017, 35, 247-254.	0.9	6
38	Does pragmatically structured outpatient dietary counselling reduce sodium intake in hypertensive patients? Study protocol for a randomized controlled trial. Trials, 2015, 16, 273.	0.7	5
39	Reproducibility of Carotid-Femoral Pulse Wave Velocity in End-Stage Renal Disease Patients: Methodological Considerations. Canadian Journal of Kidney Health and Disease, 2016, 3, 109.	0.6	5
40	Diastolic Hypotension in a Tertiary Care Hypertension Clinic: Have We Gone Too Far?. Canadian Journal of Cardiology, 2016, 32, 695-700.	0.8	5
41	Renovascular hypertension from the BCRâ€ABL tyrosine kinase inhibitor ponatinib. Journal of Clinical Hypertension, 2020, 22, 678-682.	1.0	5
42	The Canadian Society of Nephrology Methods in Developing and Adapting Clinical Practice Guidelines: A Review. Canadian Journal of Kidney Health and Disease, 2014, 1, 5.	0.6	4
43	Diet or additional supplement to increase potassium intake: protocol for an adaptive clinical trial. Trials, 2022, 23, 147.	0.7	4
44	Does Blockade of the Renin Angiotensin System Affect Sympathetic and Blood Pressure Responses to Amlodipine in Young Hypertensive Patients? <xref ref-type="author-notes" rid="fn1"><sup>*</sup></xref> <xref ref-type="author-notes" rid="fn2"><sup>â€</sup></xref> <subtitle></subtitle> . American Journal of Hypertension, 2007, 20, 1202-8.	1.0	3
45	High Anion Gap Metabolic Acidosis on Continuous Renal Replacement Therapy. Kidney International Reports, 2020, 5, 1833-1835.	0.4	3
46	Blood pressure measurement: Should technique define targets?. Journal of Clinical Hypertension, 2021, 23, 1538-1546.	1.0	3
47	Interâ€arm difference in blood pressure in patients referred to tertiary hypertension center: Prevalence, risk factors, and relevance to physicians. Journal of Clinical Hypertension, 2020, 22, 1513-1517.	1.0	3
48	Lower blood pressure target in nondiabetic proteinuric chronic kidney disease is not justified. Kidney International, 2014, 86, 855.	2.6	2
49	Intensive blood pressure lowering in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2017, 26, 197-204.	1.0	2
50	Thus Far and No Further: Should Diastolic Hypotension Limit Intensive Blood Pressure Lowering?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 80.	0.4	2
51	Thiazide diuretic-caused hyponatremia in the elderly hypertensive: will a bottle of Nepro a day keep hyponatremia and the doctor away? Study protocol for a proof-of-concept feasibility trial. Pilot and Feasibility Studies, 2018, 4, 71.	0.5	2
52	Page kidney: Rare cause of acute kidney injury after complicated renal artery angioplasty. Journal of Clinical Hypertension, 2021, 23, 1631-1633.	1.0	2
53	Cause, Consequence or confounding? The kidney in hypertension. Journal of Human Hypertension, 2019, 33, 639-640.	1.0	1
54	Acute Severe Renal Artery Stenosis Presenting as Acute Kidney Injury With Severe Hypertension and Active Urine Sediment. Canadian Journal of Cardiology, 2021, 37, 1671-1673.	0.8	1

#	Article	IF	CITATIONS
55	Attenuated Exerciseâ€heat Tolerance in Type 2 Diabetes and Hypertension. FASEB Journal, 2021, 35, .	0.2	1
56	Influence of uncomplicated, controlled hypertension on local heat-induced vasodilation in nonglabrous skin across the body. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2022, 322, R326-R335.	0.9	1
57	The effect of acute intradermal administration of ascorbate on heat loss responses in older adults with uncomplicated controlled hypertension. Experimental Physiology, 2022, 107, 834-843.	0.9	1
58	Behind the Mask. Hypertension, 2018, 72, 841-842.	1.3	0
59	Unintended Consequences: Perils of Renal Revascularization for Severe Hypertension. Canadian Journal of Cardiology, 2020, 36, 967.e9-967.e11.	0.8	0